Core Viewpoint - The actual controller of Baolingbao Biotech Co., Ltd., Mr. Dai Sichong, has expanded the shareholding plan to include a new entity, CEDARWALK BIOTECH HONG KONG LIMITED, to facilitate the acquisition of shares in the company [1][2]. Summary by Sections Shareholding Plan Overview - The original plan was to increase shareholding by 18,488,369 shares (5% of total shares) to a maximum of 36,976,738 shares (10% of total shares) starting from October 8, 2024, for a period of six months [1]. - The plan has been extended by 12 months, now set to conclude on April 7, 2026, while other details remain unchanged [2]. Addition of New Entity - CEDARWALK BIOTECH HONG KONG LIMITED has been added as a new entity to the shareholding plan, which is controlled by Mr. Dai Sichong [2][3]. - This entity will operate through a specific investment account managed by Guotou Securities Asset Management (Hong Kong) [2]. Shareholding Changes - As of February 4, 2026, the cumulative shares acquired by Shenzhen Songjing Investment Partnership and CEDARWALK BIOTECH HONG KONG LIMITED amount to 6,375,700 shares, representing 1.67531% of the total shares [3]. - The total shares acquired from November 2025 to February 2026 reached 5,076,300 shares, increasing the combined holding to 13.99607% [4]. Compliance and Commitments - The shareholding plan complies with relevant laws and regulations, ensuring that it does not affect the company's listing status or control [6]. - CEDARWALK BIOTECH HONG KONG LIMITED has committed to not reducing its holdings for six months post-acquisition [6].

Core Viewpoint - The company Baolingbao (002286.SZ) has seen significant shareholding increases from two investors, indicating potential confidence in the company's future performance [1] Group 1: Shareholding Changes - Songjing Investment increased its stake in the company by 114,400 shares in November 2025, representing 0.03006% of the total share capital [1] - Guotou Securities International Financial Holdings Co., Ltd. - Investment Plan No. 2 accumulated an increase of 4,961,900 shares from January 28, 2026, to February 4, 2026, accounting for 1.30382% of the total share capital [1] - The combined shareholding increase from both investors amounts to 5,076,300 shares, which is 1.33388% of the existing total share capital [1] Group 2: Total Shareholding - The total shareholding percentage of Songjing Investment and its concerted actions has risen to 13.99607%, triggering a change that touches the 1% threshold [1]

Core Viewpoint - The company Baolingbao (002286.SZ) has seen significant shareholding increases from two investors, indicating potential confidence in the company's future performance [1] Group 1: Shareholding Changes - Songjing Investment increased its stake in the company by 114,400 shares in November 2025, representing 0.03006% of the total share capital [1] - Guotou Securities International Financial Holdings Co., Ltd. - Investment Plan No. 2 accumulated an increase of 4,961,900 shares from January 28, 2026, to February 4, 2026, accounting for 1.30382% of the total share capital [1] - The combined shareholding increase from Songjing Investment and Guotou Securities amounted to 5,076,300 shares, which is 1.33388% of the existing total share capital [1] Group 2: Total Shareholding - The total shareholding percentage of Songjing Investment and its concerted parties has risen to 13.99607%, triggering a change that touches the 1% threshold [1]

证券代码：002286 证券简称：保龄宝 公告编号：2026-006 保龄宝生物股份有限公司关于 实际控制人控制的企业增持计划增加实施主体 暨权益变动触及1%刻度的公告 股东深圳松径投资合伙企业（有限合伙）保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 保龄宝生物股份有限公司（以下简称"公司"）实际控制人之一戴斯聪先生 控制的企业深圳松径投资合伙企业（有限合伙）（以下简称"松径投资"）原计 划于 2024 年 10 月 8 日起 6 个月内，通过深圳证券交易所系统允许的方式（包 括但不限于集中竞价、大宗交易等）增持公司股份，拟增持股份数不低于 18,488,369 股(占公司当时总股本的 5%)，不超过 36,976,738 股(占公司当时总股 本的 10%)。本次增持不设置固定价格、价格区间，前述增持主体将根据公司股 票价格波动情况及资本市场整体趋势，择机实施增持计划。具体内容详见公司 2024 年 10 月 8 日在指定信息披露媒体披露的《关于实际控制人控制的企业增持 公司股票计划的公告》。 2025 ...

Core Viewpoint - The actual controller of the company, Dai Sichong, has postponed the shareholding increase plan from October 8, 2024, to April 7, 2026, involving the entity Songjing Investment and a new foreign entity, Cedarwalk Biotech Hong Kong Limited [1] Summary by Relevant Sections - **Shareholding Increase Plan** - The shareholding increase plan was initially set to start on October 8, 2024, for a duration of six months but has been delayed to April 7, 2026 [1] - As of February 4, the cumulative increase by Songjing Investment and Guotou Securities International Financial Holdings Co., Ltd. - No. 2 Investment Plan reached 6.3757 million shares, accounting for 1.67531% of the total share capital [1] - **Recent Shareholding Changes** - From November 2025 to February 4, a total of 5.0763 million shares were increased, representing 1.33388% of the total share capital [1] - The shareholding of Songjing Investment and its concerted parties has risen to 13.99607% following the recent increases [1] - **Potential Implementation Issues** - The shareholding increase plan may not be fully implemented due to market and other factors [1]

Core Viewpoint - The company announced that its actual controller, Dai Sichong, through Shenzhen Songjing Investment Partnership (Limited Partnership) and its concerted party, Guotou Securities International Financial Holdings Co., Ltd. - No. 2 Investment Plan, will increase its shareholding by 5,076,300 shares from November 2025 to February 4, 2026, representing 1.33388% of the total share capital [1] Summary by Category - **Shareholding Increase**: The shareholding increase will result in a total of 53,264,490 shares held by Shenzhen Songjing Investment Partnership and its concerted party, raising their ownership percentage from 12.66220% to 13.99607% [1] - **Completion of Rights Change**: The rights change has been completed, although the shareholding increase plan has not yet been fully implemented and will continue to be advanced [1]

Group 1 - The agricultural processing sector increased by 0.19% on February 4, with Baolingbao leading the gains [1] - The Shanghai Composite Index closed at 4102.2, up 0.85%, while the Shenzhen Component Index closed at 14156.27, up 0.21% [1] - Baolingbao's stock price rose by 10.03% to 10.53, with a trading volume of 286,400 shares and a transaction value of 292 million yuan [1] Group 2 - The agricultural processing sector experienced a net outflow of 41.17 million yuan from institutional investors, while retail investors saw a net inflow of 58.53 million yuan [2] - The top stocks by net inflow included Baolingbao with 56.68 million yuan from institutional investors, while it faced a net outflow of 41.12 million yuan from retail investors [3] - Other notable stocks included Guangnong Sugar Industry with a net inflow of 9.79 million yuan from institutional investors and a net outflow of 934,190 yuan from retail investors [3]

Group 1 - The core point of the article is that Baolingbao has reported its total number of shareholders as of January 30, 2026, which stands at 32,739 [2]

关于控股股东部分股份拟被司法强制执行的提示性公告 证券代码：002286 证券简称：保龄宝 公告编号：2026-005 保龄宝生物股份有限公司 公司控股股东北京永裕投资管理有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 截至本公告披露日，保龄宝生物股份有限公司（以下简称"保龄宝"或"公 司"）控股股东北京永裕投资管理有限公司（以下简称"永裕投资"）持有公司股 份29,508,653股，占公司总股本的7.75%。其中，永裕投资通过信用交易担保证 券账户向渤海证券股份有限公司（以下简称"渤海证券"）开展融资融券业务， 该账户中持有本公司股份21,508,653股，全部为融资融券业务担保物，占永裕投 资所持本公司股份的72.89%，占公司总股本的5.65%。 公司于2026年1月30日收到控股股东永裕投资《告知函》，渤海证券称收到 黑龙江省哈尔滨市中级人民法院《协助执行通知书》（2025）黑01执恢369号： 因永裕投资与他人借款合同纠纷，要求渤海证券在收到该执行裁定后，对永裕 投资在渤海证券 ...

Core Viewpoint - The company announced the appointment of Liu Feng as the secretary of the board of directors, effective from the date of approval by the board until the current board's term ends [1] Group 1: Appointment Details - The sixth board of directors' fifteenth meeting will be held on December 15, 2025, to review the proposal for appointing Liu Feng as the board secretary [1] - Liu Feng is currently a director and the executive vice president of the company [1] - Liu Feng has completed the necessary training and obtained the certification required to officially assume the role of board secretary [1]